Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Repaglinide-induced factitious hypoglycemia.

B Hirshberg1, M C Skarulis, F Pucino

  • 1Division of Intramural Research, National Institute of Diabetes, Digestive and Kidney Diseases, W. G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA.

The Journal of Clinical Endocrinology and Metabolism
|February 7, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medical and surgical management of obesity and diabetes: what's new?

Diabetic medicine : a journal of the British Diabetic Association·2019
Same author

A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2016
Same author

Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial.

Circulation·2015
Same author

Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial.

Diabetes, obesity & metabolism·2015
Same author

Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA).

Diabetes/metabolism research and reviews·2015
Same author

Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study.

Diabetes, obesity & metabolism·2015
Same journal

The Extra X Chromosome and Autoimmune Susceptibility in Klinefelter Syndrome.

The Journal of clinical endocrinology and metabolism·2026
Same journal

Pathophysiology-Based Classification of Male Infertility: Evidence from an 800-patient Prospective Cohort.

The Journal of clinical endocrinology and metabolism·2026
Same journal

Parathyroid Carcinoma: From Molecular Pathogenesis to Multidisciplinary Management.

The Journal of clinical endocrinology and metabolism·2026
Same journal

Genetic and Clinical Factors Associated With Metformin Plasma Concentrations Following an Acute Metformin Challenge.

The Journal of clinical endocrinology and metabolism·2026
Same journal

Continuous glucose monitoring-derived time in range is associated with changes in arterial stiffness in type 2 diabetes.

The Journal of clinical endocrinology and metabolism·2026
Same journal

Association of the Primary Aldosteronism Severity Classification with Lateralization and Treatment Outcomes.

The Journal of clinical endocrinology and metabolism·2026
See all related articles

Repaglinide-induced factitious hypoglycemia is a rare condition. Clinical judgment is crucial for diagnosis when lab tests conflict, especially without specific drug assays.

Area of Science:

  • Endocrinology
  • Clinical Medicine
  • Pharmacology

Background:

  • Factitious hypoglycemia can mimic endogenous causes like insulinoma.
  • Repaglinide is an oral hypoglycemic agent that can be misused.
  • Diagnostic challenges arise from lack of specific drug assays.

Observation:

  • A young male presented with recurrent hypoglycemia.
  • Initial investigations revealed high proinsulin levels and positive intra-arterial calcium stimulation tests, suggesting insulinoma.
  • The patient's symptoms and laboratory findings were inconsistent with typical insulinoma presentation.

Findings:

  • The diagnosis of repaglinide-induced factitious hypoglycemia was established.
  • This diagnosis was made despite conflicting laboratory data suggestive of endogenous hyperinsulinism.

Related Experiment Videos

  • The absence of commercial repaglinide assays complicated the diagnostic process.

    • Implications:

    • This case underscores the critical role of clinical judgment in diagnosing complex endocrine disorders.
    • It highlights the need for considering exogenous drug-induced hypoglycemia even with seemingly positive endogenous markers.
    • Definitive diagnostic data is essential for guiding appropriate therapeutic interventions and patient management.